Anti-Human Claudin-18.2 Reference Antibody (Zolbetuximab, RUO) (HX126016)

Name: Anti-Human Claudin-18.2 Reference Antibody (Zolbetuximab, RUO)
Brand: abinScience
SKU: HX126016
Price: 176 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号	HX126016
説明	Zolbetuximab (HX126016) is a research-grade recombinant antibody targeting Claudin-18. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性	Human
アプリケーション	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
宿主種	Chimeric
クローン性	Monoclonal
アイソタイプ	IgG1-kappa
テスト済みアプリケーション	FCM
ターゲット	CLDN18.2, Claudin-18.2
エンドトキシンレベル	< 10 EU/mg
純度	>95% as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	P56856-2
形態	Liquid
保存バッファー	0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名	Claudin18.2, GC-182, IMAB-362, IMAB362, Claudiximab, 1496553-00-4
背景	Claudin-18 (CLDN18.2) is a ~27 kDa protein. Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling. Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier. Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription. Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency. Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways. CLDN18.2 is the therapeutic target of zolbetuximab (Vyloy).
注意事項	For research use only. Not suitable for clinical or therapeutic use.

イメージ

Bioactivity

SEC-HPLC detection for Research Grade Zolbetuximab.
Flow Cytometry

Flow-cytometry using anti-human Claudin18.2 antibody. Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an anti-human Claudin18.2 monoclonal antibody (Catalog HX126016) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a Goat Anti-Human IgG H&L Polyclonal Antibody, AF647 (abinScience: HF690324) and cells analysed on a NovoCyte Flow Cytometer.
SDS-PAGE

SDS-PAGE for Research Grade Zolbetuximab.